Share on StockTwits

Stock analysts at Stifel Nicolaus initiated coverage on shares of Puma Biotechnology (NASDAQ:PBYI) in a report issued on Tuesday. The firm set a “hold” rating on the stock.

Several other analysts have also recently commented on the stock. Analysts at Citigroup Inc. raised their price target on shares of Puma Biotechnology from $99.00 to $292.00 in a research note on Wednesday, July 23rd. They now have a “buy” rating on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Puma Biotechnology from $144.00 to $300.00 in a research note on Wednesday, July 23rd. They now have an “outperform” rating on the stock.

Shares of Puma Biotechnology (NASDAQ:PBYI) opened at 261.83 on Tuesday. Puma Biotechnology has a 52-week low of $33.70 and a 52-week high of $262.48. The stock has a 50-day moving average of $155.7 and a 200-day moving average of $106.3. The company’s market cap is $7.886 billion.

Puma Biotechnology (NASDAQ:PBYI) last posted its quarterly earnings results on Monday, August 11th. The company reported ($1.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.66) by $0.39. Analysts expect that Puma Biotechnology will post $-3.81 EPS for the current fiscal year.

Puma Biotechnology, Inc is a development-stage biopharmaceutical company that acquires and develops products for the treatment of various forms of cancer.

Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.